首页 | 本学科首页   官方微博 | 高级检索  
     


Comparison of pharmacokinetics and dynamics of two dosage regimens of foscarnet in AIDS patients with Cytomegalovirus retinitis
Authors:F. Castelli  L. Tomasoni  C. Zeroli  F. Suter  G. Trespi  G. Carosi  A. Hedman
Affiliation:Clinic of Infectious and Tropical Diseases, University of Brescia, Italy, IT
Second Division of Infectious Diseases, Spedali Civili of Brescia, Italy, IT
Division of Infectious Diseases, Varese General Hospital, Italy, IT
Division of Infectious Diseases, Busto Arsizio General Hospital, Italy, IT
Medical Department, Astra Farmaceutici, Milan, Italy, IT
Department of Clinical Pharmacology, Astra Arcus AB, S-15185 S?dert?lje, Sweden, SE
Abstract:Objective: To compare the pharmacokinetics of foscarnet administered as an infusion twice daily (BID) or thrice daily (TID), and to compare the effects on the electrolyte balance, cardiac and renal functions over a 3-week induction treatment of Cytomegalovirus (CMV) retinitis. Methods: Pharmacokinetics/dynamics of foscarnet were investigated on treatment days 1, 14 and 21. Twelve AIDS patients with CMV retinitis completed the investigation period. Concentrations of foscarnet and electrolytes were assayed by high-performance liquid chromatography (HPLC) and by an ion-selective analyser, respectively. Results: The pharmacokinetics of the two regimens were essentially similar. Foscarnet plasma and creatinine clearances were 2.0 and 1.6 ml · min−1 · kg−1, respectively, in the BID group at steady state (day 21). In the TID group the corresponding values were 1.8 and 1.7 ml · min−1 · kg−1, respectively. In both regimens the elimination half-life of foscarnet was 2–3 h. Ionized calcium concentrations were transiently decreased and strongly inversely correlated to foscarnet plasma concentrations in both regimens with no significant differences between groups. A trend towards prolongation of the QTc interval was seen when data from both treatments were analysed together. Conclusion: Our data suggest comparable pharmacokinetics of foscarnet after intermittent administration BID or TID during a 3-week induction period. Received: 22 January 1996 / Accepted in revised form: 6 November 1996
Keywords:Foscarnet  HIV  Cytomegalovirus (CMV)   dosage regimens
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号